Search the database for deliberate release of GM medicinal products
Displaying 1 - 7 of 7
|EU record number
|Company / Sponsor
|Phase I study to assess safety, tolerability and immunogenicity of the hRVFV-4s vaccine in healthy subjects
|Wageningen Bioveterinary Research (Larissa Consortium)
|hRVFV-4s is a four segments human Rift Valley fever virus vaccine, which derives from a natural clone (Clone 13) that lacks 69% of the gene NSs, a major virulence determinant of the virus. The hRVFV-4s vaccine is further attenuated by splitting the M genome segment into two M-type segments.
|A phase II, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
|BCMA02 (human B cell maturation antigen)-CAR
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2018.
|A Phase I/II study of the safety and efficacy of a single dose of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells in subjects with severe sickle disease
|CRISPR Therapeutic AG
|Modified cells expressing Hemoglobin F (HbF)
|Only notified under the "contained use" procedure. Dossier submitted on 24/04/2018.
|A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of jcar017 in adult subjects with aggressive b-cell non-hodgkin lymphoma
|EGFRt en chimeric antigen receptor against CD19
|A phase III, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
|BCMA02 (human B cell maturation antigen) -Chimeric antigen receptor
|Only notified under the "contained use" procedure. Dossier submitted on 23/11/2016.
|A phase 2, open-label, multi-cohort, single-arm, multi-center trial to determine the safety, feasibility, and efficacy of JCAR015 in adult subjects with B-cell acute lymphoblastic leukemia
|Chimeric antigen receptor against CD19
|Only notified under the "contained use" procedure. Dossier submitted on 08/07/2010.
|An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults.
|Institut Pasteur - Paris
|Gag, Pol, Nef genes of HIV